Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 12, 2026 8:00 AM EST

Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024

Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected

Launched Alnylam 2030 Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results

Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings

Reiterates Net Product Sales Guidance and Provides Additional 2026 Financial Guidance

... More